GoodRx Employer Direct opens GLP 1 drug pricing to all US employers

Employers anywhere in the United States can now sign up for GoodRx Employer Direct, a program that lets them pay part or all of the cost of approved GLP 1 weight loss drugs outside their health plan. GoodRx announced the wider rollout on October 29, 2026, building on a model it first introduced in February. The program uses employer prices that drugmakers offer for five products, among them Wegovy and the Zepbound KwikPen. What a worker will pay at the pharmacy counter was not disclosed and will depend on each employer's choices.

How GoodRx Employer Direct works

The program hands three decisions to the employer, according to GoodRx. First, the company picks which products to include from a list of five: the Wegovy injection, Wegovy HD, the Wegovy pill, Foundayo and the Zepbound KwikPen. Second, it sets its contribution, which can be a fixed dollar amount, a percentage of the cost or full coverage. GoodRx says the employer's share comes off automatically at the pharmacy when the drug is dispensed, so the worker does not pay first and claim money back later. Third, the employer decides whether to add clinical care through GoodRx for Weight Loss. Workers holding a prescription from their own doctor can still join, so the program does not force anyone to switch to the GoodRx clinic.

The design sits next to an employer's health plan rather than inside it, GoodRx says, and a new client can be set up in as little as 30 days. Withum is the one employer named so far. It said it wanted control over which drugs get funded and the size of its contribution, with spending it can predict. From January 2027, GoodRx Companion, the company's paid subscription for generic drug and health care savings, can also be bolted onto the same employer channel. The reports we reviewed do not say how many employers have signed up, what GoodRx charges them in fees, or how many workers are enrolled today. Those numbers will show whether the GoodRx Employer Direct rollout reaches many people.

Lilly Employer Connect sets the Zepbound price

The only employer price on the record comes from Lilly. On March 5, 2026, the company launched Lilly Employer Connect, a platform that links employers with outside program administrators, and GoodRx was on its launch list of more than fifteen. Through that platform, Lilly said it sells the Zepbound KwikPen to network pharmacies at $449 for every dose. The Lilly Employer Connect announcement named HealthDyne and CenterWell as dispensing pharmacies in that network. GoodRx says it is an approved administrator for the platform. On the other side, Novo Nordisk works with GoodRx on its own employer pricing for the Wegovy products, but no Wegovy figure appeared in the GoodRx announcement as reported or in any other material we reviewed.

Through that platform, Lilly said it sells the Zepbound KwikPen to network pharmacies at $449 for every dose.

That $449 is not what a worker pays. Lilly said an employer's final bill can shift depending on which pharmacy and administrator it uses. It added that a worker's out of pocket share turns on the cost share design the employer selects, plus any dispensing and service charges set with the administrator. According to Novo, the GoodRx tie up is meant to put Wegovy employer pricing within reach at retail drugstores across the country. Other administrators are building similar routes, and our report on direct to employer Wegovy at Andel found no prices, start dates or client names. For readers comparing programs, the point to hold on to is simple: this is a drugmaker price passed through an administrator, and it sits outside the health plan.

What workers may pay under employer GLP 1 coverage

For a worker, the answer depends almost entirely on the employer. A company that chooses full coverage may leave little to pay, while one that offers a fixed amount leaves the worker paying the gap between that amount and the program price, plus any fees. Neither GoodRx nor Lilly gave a sample bill for an employee. The reports also do not say whether money spent through the program counts toward a health plan deductible, which matters for anyone with other medical costs that year. A prescriber still has to judge the drug appropriate, so the program changes who pays rather than who qualifies medically. Workers whose employer skips the offering stay with whatever their plan already covers for weight loss.

GoodRx chief executive Wendy Barnes said many employers already want to support these drugs, and the open question is "how to make it affordable for employees and manageable within their benefits budgets." That pressure is visible across the market. A WTW survey we covered this week found that 53% of larger employers cover GLP 1 drugs for weight loss, down from 57%, as employer GLP 1 coverage shrinks ahead of 2027. A side program lets a company fund the drugs without putting them back on its plan formulary, and it fixes the company's spending at whatever contribution it sets. That is the predictability Withum described. Whether it also lowers total spending for employers is not shown by any data released so far.

Why GoodRx and the drugmakers want this channel

GoodRx has a business reason to grow this channel. Its Pharma Direct revenue, which comes from its work with drugmakers, reached $61.6 million in the second quarter, up 76% from a year earlier, Pharmaceutical Commerce reported, citing GoodRx results. Drugmakers have their own reasons. When it launched Employer Connect, Lilly said about half of workers with commercial insurance have no coverage for obesity drugs, and it described the platform as a way to close that gap. Lilly is also selling more volume at lower realized prices, as our look at Lilly third quarter earnings showed. Employer programs like this one give both companies another route to patients whose insurers will not pay, without waiting for plans to change their formularies.

The two drugmakers whose products fill the list are also fighting in court. On October 26, US District Judge Zahid Quraishi in New Jersey refused to issue the preliminary injunction Novo Nordisk sought against Lilly's comparison ads for Zepbound and Mounjaro, according to the Pharmaceutical Commerce roundup. Novo sued in July, claiming the ads set higher doses of Lilly's drugs against lower doses of Wegovy and Ozempic. The judge found no irreparable harm, pointing out that Novo's prescription numbers stayed flat during the April to July run of the ads. The Novo Lilly ad ruling leaves open whether the comparisons were misleading, and the lawsuit goes on. Employers weighing the two brands should expect the marketing contest to continue.

Conclusion

GoodRx Employer Direct gives any US employer a way to fund approved GLP 1 weight loss drugs at drugmaker prices without changing its health plan. The one public figure is Lilly's $449 pharmacy price for the Zepbound KwikPen. Worker costs, fees, enrollment and any Wegovy employer price remain undisclosed. Readers should treat the program as an employer choice, not a new right to coverage, and check with their benefits team before assuming it applies to them.